⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for phase 1 trial

Every month we try and update this database with for phase 1 trial cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001NCT03301688
NSCLC
Toripalimab
18 Years - 70 YearsShanghai Junshi Bioscience Co., Ltd.
A Clinical Study of TAB006 in Patients With Previously Treated, Advanced MalignanciesNCT05253105
Previously Trea...
Malignancies
TAB006
Toripalimab
18 Years - Shanghai Junshi Bioscience Co., Ltd.
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant LymphomaNCT03316144
Malignant Lymph...
Toripalimab
18 Years - 65 YearsShanghai Junshi Bioscience Co., Ltd.
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced MalignanciesNCT03474640
Advanced Malign...
Toripalimab, Re...
18 Years - Shanghai Junshi Bioscience Co., Ltd.
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced MalignanciesNCT03474640
Advanced Malign...
Toripalimab, Re...
18 Years - Shanghai Junshi Bioscience Co., Ltd.
A Clinical Study of TAB006 in Patients With Previously Treated, Advanced MalignanciesNCT05253105
Previously Trea...
Malignancies
TAB006
Toripalimab
18 Years - Shanghai Junshi Bioscience Co., Ltd.
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant LymphomaNCT03316144
Malignant Lymph...
Toripalimab
18 Years - 65 YearsShanghai Junshi Bioscience Co., Ltd.
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced MalignanciesNCT04137900
Advanced Unrese...
Metastatic Soli...
TAB004
Toripalimab
18 Years - TopAlliance Biosciences
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid TumorsNCT02836834
Lymphoma
Lung Cancer
JS001
18 Years - 65 YearsShanghai Junshi Bioscience Co., Ltd.
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: